Business
Keynote Address at 8th Annual Photodynamic Day
Ondine Biomedical Inc. announced that its President and Chief Technology Officer delivered a keynote address at the 8th Annual Photodynamic Day in Türkiye, highlighting the company's non-antibiotic nasal photodisinfection technology, Steriwave. The presentation showcased clinical evidence demonstrating Steriwave's potential to reduce surgical site infections, citing a 78% reduction in complex brain surgery at Leeds Teaching Hospitals and a 71% reduction in hip and knee arthroplasty infections at Mid Yorkshire Teaching NHS Trust, alongside positive health economic outcomes. The company also provided an update on its completed LANTERN Phase 3 clinical trial, which enrolled 5,188 patients across 18 hospitals in the United States and Canada. Disclaimer*
About this update from Ondine Biomedical, Inc.
1 July 2026 ONDINE BIOMEDICAL INC. ("Ondine Biomedical", "Ondine", or "the Company") Ondine Biomedical Keynote Address at 8th Annual Photodynamic Day in Türkiye Ondine Biomedical Inc. (AIM: OBI), a leader in light-activated antimicrobial therapies to prevent and treat hospital infections, announces that Dr. Nicolas Loebel, President and Chief Technology Officer, delivered the keynote address at the 8th Annual Photodynamic Day in Istanbul, Türkiye, on 25 June 2026. This prestigious invitation reflects Ondine's growing global recognition within the photodynamic therapy (PDT) community for its pioneering work in advancing antimicrobial photodynamic therapy (aPDT), also known as photodisinfection. Hosted by Acıbadem University under the stewardship of Professor Fabienne Dumoulin, a leading authority on photodynamic photosensitisers, and held in conjunction with the International Photodynamic Association (IPA), the event brought together leading researchers, clinicians and industry experts working to advance photodynamic therapy ahead of the 20th IPA World Congress, which will take place in Türkiye from 12-16 July 2027. The event also provided an opportunity to engage with international clinical and scientific leaders as photodisinfection continues to gain momentum as a non-antibiotic approach to infection prevention. During his keynote, Dr. Loebel presented clinical and real-world evidence from leading healthcare institutions in the United Kingdom and Canada, demonstrating the potential of Ondine's non-antibiotic nasal photodisinfection technology, Steriwave® to reduce surgical site infections ("SSIs") across multiple surgical specialties, while supporting improved patient outcomes and cost savings to healthcare systems. The presentation also highlighted the growing body of evidence supporting antimicrobial photodisinfection as a clinician-led, non-antibiotic approach to infection prevention. As healthcare systems seek effective strategies to address healthcare-associated infections and antimicrobial resistance ("AMR"), photodisinfection has the potential to support antimicrobial stewardship while helping reduce the clinical and economic burden of healthcare-associated infections. Dr Loebel also provided an update on the Company's recently completed LANTERN Phase 3 clinical trial, which enrolled 5,188 patients across 18 hospitals in the United S...
View stock analysis, news, and events for Ondine Biomedical, Inc.